Matches in SemOpenAlex for { <https://semopenalex.org/work/W3000646538> ?p ?o ?g. }
Showing items 1 to 94 of
94
with 100 items per page.
- W3000646538 abstract "ABSTRACT Introduction In Japan, capecitabine is mainly used in combination with oxaliplatin (XELOX) in treatment for metastatic colorectal cancer (mCRC) since its approval in 2010. The results of capecitabine plus Irinotecan (CPT) (XELIRI) with or without bevacizumab (BV) in EU patients (pts) were previously reported, but not in Japanese. Thus, we conducted this study to assess the safety and efficacy of XELIRI plus BV in Japanese pts with mCRC. Methods Pts with prior chemotherapy including oxaliplatin and BV for mCRC, wild or hetero type of UGT1A1 *6*28 were eligible for this study. Therapy consisted of capecitabine 800 mg/m2 bid on days1-15, CPT 200 mg/m2 on day 1, and BV 7.5mg/kg on day 1, q21 days. Primary endpoint was incidence of Dose limiting Toxicity (DLT) in phase I part and progression free survival (PFS) in phase II part. Results Total 34 pts (6 pts in phase I part, 28 pts in phase II part) were enrolled from May 2010 to June 2011. Baseline characteristics were median age of 60 years (range, 22-74); PS 0/1 (22/12 pts); male/female (24/10 pts), UGT1A1 wild/*6hetero/*28hetero (21/7/6 pts), prior treatments FOLFOX4+BV/mFOLFOX6+BV/XELOX+BV/others (1/15/10/8) and reasons for 2nd-line treatment progression disease/others (33/1 pts).DLT was not appeared in phase I part. The median PFS was 8.3 months (95%CI, 6.3-11.3). The best overall response rate was 18 %, and disease control rate was 88%. The most frequently related adverse event were neutropenia (any grade: 53%, grade3/4: 9%), diarrhea (any grade: 50%, grade 3/4: 9%), and hand-foot syndrome (any grade: 44%, grade 3/4: 0%). Conclusion This study suggested that XELIRI+BV regimen had shown well-tolerated and effective as 2nd-line treatment for mCRC in Japanese pts. This regimen seems to be appropriate for using for Oxaliplatin based regimen resistant." @default.
- W3000646538 created "2020-01-23" @default.
- W3000646538 creator A5003533726 @default.
- W3000646538 creator A5011974412 @default.
- W3000646538 creator A5029765609 @default.
- W3000646538 creator A5038655401 @default.
- W3000646538 creator A5041844936 @default.
- W3000646538 creator A5044846389 @default.
- W3000646538 creator A5058441704 @default.
- W3000646538 creator A5079864042 @default.
- W3000646538 creator A5081294000 @default.
- W3000646538 creator A5087491730 @default.
- W3000646538 creator A5089442498 @default.
- W3000646538 creator A5090659723 @default.
- W3000646538 date "2012-06-01" @default.
- W3000646538 modified "2023-09-28" @default.
- W3000646538 title "P-0244 A Phase I/II Study of Tri-Weekly Xeliri Plus Bevacizumab for Japanese Patients with MCRC as Second-Line Chemotherapy (Bix Study)" @default.
- W3000646538 doi "https://doi.org/10.1016/s0923-7534(20)30172-1" @default.
- W3000646538 hasPublicationYear "2012" @default.
- W3000646538 type Work @default.
- W3000646538 sameAs 3000646538 @default.
- W3000646538 citedByCount "1" @default.
- W3000646538 countsByYear W30006465382014 @default.
- W3000646538 crossrefType "journal-article" @default.
- W3000646538 hasAuthorship W3000646538A5003533726 @default.
- W3000646538 hasAuthorship W3000646538A5011974412 @default.
- W3000646538 hasAuthorship W3000646538A5029765609 @default.
- W3000646538 hasAuthorship W3000646538A5038655401 @default.
- W3000646538 hasAuthorship W3000646538A5041844936 @default.
- W3000646538 hasAuthorship W3000646538A5044846389 @default.
- W3000646538 hasAuthorship W3000646538A5058441704 @default.
- W3000646538 hasAuthorship W3000646538A5079864042 @default.
- W3000646538 hasAuthorship W3000646538A5081294000 @default.
- W3000646538 hasAuthorship W3000646538A5087491730 @default.
- W3000646538 hasAuthorship W3000646538A5089442498 @default.
- W3000646538 hasAuthorship W3000646538A5090659723 @default.
- W3000646538 hasBestOaLocation W30006465381 @default.
- W3000646538 hasConcept C121608353 @default.
- W3000646538 hasConcept C126322002 @default.
- W3000646538 hasConcept C143998085 @default.
- W3000646538 hasConcept C203092338 @default.
- W3000646538 hasConcept C2776694085 @default.
- W3000646538 hasConcept C2776705615 @default.
- W3000646538 hasConcept C2777802072 @default.
- W3000646538 hasConcept C2777909004 @default.
- W3000646538 hasConcept C2780259306 @default.
- W3000646538 hasConcept C2780962732 @default.
- W3000646538 hasConcept C31760486 @default.
- W3000646538 hasConcept C526805850 @default.
- W3000646538 hasConcept C535046627 @default.
- W3000646538 hasConcept C71924100 @default.
- W3000646538 hasConcept C90924648 @default.
- W3000646538 hasConceptScore W3000646538C121608353 @default.
- W3000646538 hasConceptScore W3000646538C126322002 @default.
- W3000646538 hasConceptScore W3000646538C143998085 @default.
- W3000646538 hasConceptScore W3000646538C203092338 @default.
- W3000646538 hasConceptScore W3000646538C2776694085 @default.
- W3000646538 hasConceptScore W3000646538C2776705615 @default.
- W3000646538 hasConceptScore W3000646538C2777802072 @default.
- W3000646538 hasConceptScore W3000646538C2777909004 @default.
- W3000646538 hasConceptScore W3000646538C2780259306 @default.
- W3000646538 hasConceptScore W3000646538C2780962732 @default.
- W3000646538 hasConceptScore W3000646538C31760486 @default.
- W3000646538 hasConceptScore W3000646538C526805850 @default.
- W3000646538 hasConceptScore W3000646538C535046627 @default.
- W3000646538 hasConceptScore W3000646538C71924100 @default.
- W3000646538 hasConceptScore W3000646538C90924648 @default.
- W3000646538 hasLocation W30006465381 @default.
- W3000646538 hasOpenAccess W3000646538 @default.
- W3000646538 hasPrimaryLocation W30006465381 @default.
- W3000646538 hasRelatedWork W1780046184 @default.
- W3000646538 hasRelatedWork W1978028546 @default.
- W3000646538 hasRelatedWork W1986004507 @default.
- W3000646538 hasRelatedWork W2067495120 @default.
- W3000646538 hasRelatedWork W2158120152 @default.
- W3000646538 hasRelatedWork W2214085593 @default.
- W3000646538 hasRelatedWork W2220367249 @default.
- W3000646538 hasRelatedWork W2227477053 @default.
- W3000646538 hasRelatedWork W2242445106 @default.
- W3000646538 hasRelatedWork W2261913233 @default.
- W3000646538 hasRelatedWork W2322553328 @default.
- W3000646538 hasRelatedWork W2388758644 @default.
- W3000646538 hasRelatedWork W2397750262 @default.
- W3000646538 hasRelatedWork W2525759112 @default.
- W3000646538 hasRelatedWork W2589479492 @default.
- W3000646538 hasRelatedWork W2590231172 @default.
- W3000646538 hasRelatedWork W2590284672 @default.
- W3000646538 hasRelatedWork W2999983310 @default.
- W3000646538 hasRelatedWork W3000367520 @default.
- W3000646538 hasRelatedWork W3000602862 @default.
- W3000646538 isParatext "false" @default.
- W3000646538 isRetracted "false" @default.
- W3000646538 magId "3000646538" @default.
- W3000646538 workType "article" @default.